Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Bone-Specific Agents for Drug Delivery

The advantage of this drug delivery system is the ability to directly target specific skeletal sites of disease, while also being able to administer the lowest, clinically effective dose possible, thereby lowering the potential for harmful side effec

Full description

Summary

Current technologies for the treatment of cancer bone metastasis involve non-specific administering drugs at their free form. To be able to reach bone lesions through systemic administration, the drug concentration usually should be administered at its highest allowed concentration for prolonged period of time, which significantly increases treatment side effects. Researchers at the University of Nebraska Medical Center have developed a novel drug delivery system, which upon the administration directly reached and specifically binds to bones. Since the drugs are directly delivered to the bone, the toxic side effects of devastating cancer chemotherapy side effects are significantly reduced and lower drug concentrations can be used. In addition the novel technology allows manipulation with the degree of binding of delivery system to a bone tissue. This adds additional advantage of controlling the kinetics of distribution of drug in the body.

Market Value

One of the major problems with drug treatments for bone cancer and other bone diseases is drug treatments must be administered nonspecifically and at very high doses. This is problematic because these drugs come in contact with nearly every tissue in the body, often exerting toxic side effects. The advantage of this drug delivery system is the ability to directly target specific skeletal sites of disease, while also being able to administer the lowest, clinically effective dose possible, thereby lowering the potential for harmful side effects.

Features & Benefits

  • Specific drug delivery system bone diseases
  • Significantly decreases toxicity of treatments
  • System of delivery can be easily manipulated to vary degree of bone-binding

Development status

Early Stage

Patent information

TID 132

Type of business relationship sought

UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with the University of Nebraska Medical Center.

Licensing contact

Dr. Jack Hartwigsen
Sr. Licensing Associate
Request more information

More information

For more information about the product please visit website.

Company details

University of Nebraska Medical Center / UNeMed Corporation
Technology Marketing and Licensing for The University of Nebraska Medical Center

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Partnering consultation free of charge
BioPharm America
Biotech Patents
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us